Board meeting on Oct 28 to consider Q2 FY26 financial results

Results View source PDF Explain this filing

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹990.00

prior close

₹984.20

announcement price

In-mkt

timing

Nifty Microcap 250market-2.6%+1.1% vs market

Specialty Chemicals peers, median of 100sector-3.3%+1.8% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

+0.2

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-2.6+1.1-3.3+1.8

Next day

-3.1-3.6+0.5-4.3+1.2

-3.0-5.8+2.8-7.0+3.9

-0.4-5.5+5.1-6.6+6.2

+3.6pendingpending-5.5+9.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 100Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudeep Pharma has informed BSE that its Board of Directors will meet on Wednesday, 28th October 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2026, along with other business items. The trading window for insiders is closed from 1st October 2026 till 30th October 2026. This is a routine pre-results intimation under SEBI listing rules.

Likely market impact

Routine board meeting intimation ahead of Q2 results announcement; stock may react on 28 Oct depending on outcome.